Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Qi Wang, Qingfa Bu, Zibo Xu, Yuan Liang, Jinren Zhou, Yufeng Pan, Haoming Zhou, Ling Lu

Clin Mol Hepatol. 2024;30(3):515-538. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0107

View: 2258 Download: 219

Pil Soo Sung

Clin Mol Hepatol. 2022;28(3):333-350. Published online October 19, 2021

DOI: https://doi.org/10.3350/cmh.2021.0308

View: 17326 Download: 372 Web of Science: 23 Crossref: 25

Yusuke Watanabe, Atsunori Tsuchiya, Shuji Terai

Clin Mol Hepatol. 2021;27(1):70-80. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0194

View: 12571 Download: 405 Web of Science: 77 Crossref: 80

Junjie Yu

Received June 11, 2024 Accepted June 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0443 [Epub ahead of print]

View: 506 Download: 32

1 |

Viewed By 5958	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5450	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 5211	MAFLD: How is it different from NAFLD?
Viewed By 5199	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4770	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 208	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 145	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 119	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 107	MAFLD: How is it different from NAFLD?
Cited By 94	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search